The company Seattle Genetics may move into new areas of research and treatment. It has long focused on blood cancers, but it is looking at developing therapies for solid tumor setting. Trials have already been conducted in which positive results were achieved in treatment for these tumors in the early stages of cancer. The company has produced an antibody-drug conjugate. It has proven to be effective in some patients who suffer from breast cancer that is triple-negative metastatic. This type of cancer has been very hard to treat in the past, and that is why the success seen in Seattle Genetics’s research has been so encouraging to so many.
This new drug is made from targeted monoclonal antibodies that are connected to a payload which kills cancer cells. It is just one of four potential candidates that Seattle Genetics is testing in the lab right now. The results showed a 37% response rate within patients. These are patients who are no longer responding to other methods of treatment. Experts say these results are very impressive given that the drug is just a single agent. This could mean impressive gains to Seattle Genetics’s stock price in the coming days.
When it comes to breast cancer, nearly 20% of new cases are triple negative. This means that they do not have the classical biomarkers that enable early detection of the cancer. The total number of new cases per year is 1.67 million. This type of cancer is very devastating and those who are diagnosed with it often have a poor prognosis.
Seattle Genetics was founded by Dr. Clay Siegall. He became a board member of Ultragenyx in 2014. He is not only the CEO of Seattle Genetics but also the Chairman of the Board. He founded the company in 1998 because he had a dream of helping people through discovering new ways of treating cancer and other diseases. Dr. Siegall got his Bachelors degree in Zoology and pursued a Ph.D. in Genetics which he earned at George Washington University. He continues to pioneer new methods of treatment through his company. He is a man devoted to saving lives.